Trade Mark Journal No.2026/002 9 January 2026

UK00004313488 19 December 2025 (5)

UPCLIXIOR

International priority date claimed: 10 November 2025 (United States of America) (99488513)

Class 5: Pharmaceutical preparations for the treatment and prevention of of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants.

Bristol-Myers Squibb Company

Representative: Sipara Limited